Emcure Pharmaceuticals announced robust financial results for FY26, with annual revenue crossing the $1 billion mark. The company reported a 16.6% year-on-year revenue growth for the full fiscal year and a 16.7% increase in the final quarter. Performance was driven by strong international momentum, strategic buyouts, and sustained growth in key therapeutic areas like oncology and cardiac care, leading to a significant 41% growth in adjusted profit after tax for the year.
Financial Highlights for FY26
Emcure Pharmaceuticals delivered strong performance throughout the 2026 fiscal year, achieving a milestone annual revenue of ₹9,204 crore, representing a 16.6% year-on-year growth. The company’s profitability also saw substantial improvements, with EBITDA reaching ₹1,789 crore, a 21.8% increase over the previous year, and an EBITDA margin of 19.4%. The adjusted Profit After Tax (PAT) rose by 40.9% to ₹1,008 crore, underscoring the success of its strategic growth initiatives.
Strong Quarterly Performance
For the fourth quarter ended March 31, 2026, Emcure reported revenue from operations of ₹2,470 crore, up 16.7% year-on-year. The company’s EBITDA for the quarter was ₹485 crore, with margins improving to 19.7%. The adjusted PAT for the quarter stood at ₹279 crore, reflecting a solid 36% growth compared to the same period in the previous year.
Segmental Growth and Strategic Expansion
The company’s international business remains a core growth driver, contributing ₹5,177 crore in annual sales, a 22.2% year-on-year increase, fueled by strong base business momentum and new product launches. Domestically, Emcure achieved ₹4,027 crore in sales, a 10% growth led by cardiac, CNS, and oncology divisions. During the year, the company focused on long-term value creation through in-licensing, the Zuventus minority buyout, and targeted acquisitions in the UK and Canada, while continuing to invest in its complex injectables and biosimilars pipeline.
Source: BSE
